TY - JOUR
T1 - Adaptive Radiation Therapy (ART) Strategies and Technical Considerations
T2 - A State of the ART Review From NRG Oncology
AU - Glide-Hurst, Carri K.
AU - Lee, Percy
AU - Yock, Adam D.
AU - Olsen, Jeffrey R.
AU - Cao, Minsong
AU - Siddiqui, Farzan
AU - Parker, William
AU - Doemer, Anthony
AU - Rong, Yi
AU - Kishan, Amar U.
AU - Benedict, Stanley H.
AU - Li, X. Allen
AU - Erickson, Beth A.
AU - Sohn, Jason W.
AU - Xiao, Ying
AU - Wuthrick, Evan
N1 - Funding Information:
Disclosures: S.H.B., Y.R., and Y.X. have nothing to disclose. M.C. reports personal fees from ViewRay Inc and Varian Inc, outside the submitted work. A.D. reports honoraria and lecturing for ViewRay Inc. B.A.E. reports departmental research support from Elekta, outside the submitted work. C.K.G.-H. reports travel and honoraria for speaking engagements from ViewRay Inc; advisory board membership and a master research agreement from Philips Healthcare; grants from NIH, National Cancer Institute of the National Institutes of Health under Award Number R01CA204189; and a research agreement from Modus Medical, outside the submitted work. A.U.K. reports honoraria from and consulting for Varian Medical Systems; a grant and honoraria from ViewRay Inc; advisory board membership for Janssen; and consulting fees from Intelligent Automation, outside the submitted work. P.L. reports personal fees and nonfinancial support from ViewRay Inc; grants, personal fees, and nonfinancial support from AstraZeneca Inc; and personal fees and nonfinancial support from Varian Inc, outside the submitted work. X.A.L. reports research grants to institution from Elekta AB, Manteia Med, and Siemens Med, outside the submitted work. In addition, X.A.L. has a patent/license on ART techniques. J.R.O. reports in the past (>48 months ago) receiving industry research funding in support of MR guided radiation therapy and travel/speaking fees to give presentations on MR guided radiation therapy. W.P. reports being an employee of McGill University Health Centre, outside the submitted work. F.S. reports honoraria for talks and lectures from Varian Medical Systems Inc and for site surveys from the American College of Radiology, during the conduct of the study. E.W. reports personal fees from Varian and Sanofi/Regeneron, outside the submitted work. A.D.Y reports grants and personal fees from Varian Medical Systems, outside the submitted work; In addition, A.D.Y has a patent pending adaptive radiotherapy phantom. J.W.S. discloses grants from NIH under award numbers R21DE028690 and R01CA187053 outside of the submitted work.
Funding Information:
Disclosures: S.H.B., Y.R., and Y.X. have nothing to disclose. M.C. reports personal fees from ViewRay Inc and Varian Inc, outside the submitted work. A.D. reports honoraria and lecturing for ViewRay Inc. B.A.E. reports departmental research support from Elekta, outside the submitted work. C.K.G.-H. reports travel and honoraria for speaking engagements from ViewRay Inc; advisory board membership and a master research agreement from Philips Healthcare; grants from NIH, National Cancer Institute of the National Institutes of Health under Award Number R01CA204189; and a research agreement from Modus Medical, outside the submitted work. A.U.K. reports honoraria from and consulting for Varian Medical Systems; a grant and honoraria from ViewRay Inc; advisory board membership for Janssen; and consulting fees from Intelligent Automation, outside the submitted work. P.L. reports personal fees and nonfinancial support from ViewRay Inc; grants, personal fees, and nonfinancial support from AstraZeneca Inc; and personal fees and nonfinancial support from Varian Inc, outside the submitted work. X.A.L. reports research grants to institution from Elekta AB, Manteia Med, and Siemens Med, outside the submitted work. In addition, X.A.L. has a patent/license on ART techniques. J.R.O. reports in the past (>48 months ago) receiving industry research funding in support of MR guided radiation therapy and travel/speaking fees to give presentations on MR guided radiation therapy. W.P. reports being an employee of McGill University Health Centre, outside the submitted work. F.S. reports honoraria for talks and lectures from Varian Medical Systems Inc and for site surveys from the American College of Radiology, during the conduct of the study. E.W. reports personal fees from Varian and Sanofi/Regeneron, outside the submitted work. A.D.Y reports grants and personal fees from Varian Medical Systems, outside the submitted work; In addition, A.D.Y has a patent pending adaptive radiotherapy phantom. J.W.S. discloses grants from NIH under award numbers R21DE028690 and R01CA187053 outside of the submitted work.
Publisher Copyright:
© 2020
PY - 2021/3/15
Y1 - 2021/3/15
N2 - The integration of adaptive radiation therapy (ART), or modifying the treatment plan during the treatment course, is becoming more widely available in clinical practice. ART offers strong potential for minimizing treatment-related toxicity while escalating or de-escalating target doses based on the dose to organs at risk. Yet, ART workflows add complexity into the radiation therapy planning and delivery process that may introduce additional uncertainties. This work sought to review presently available ART workflows and technological considerations such as image quality, deformable image registration, and dose accumulation. Quality assurance considerations for ART components and minimum recommendations are described. Personnel and workflow efficiency recommendations are provided, as is a summary of currently available clinical evidence supporting the implementation of ART. Finally, to guide future clinical trial protocols, an example ART physician directive and a physics template following standard NRG Oncology protocol is provided.
AB - The integration of adaptive radiation therapy (ART), or modifying the treatment plan during the treatment course, is becoming more widely available in clinical practice. ART offers strong potential for minimizing treatment-related toxicity while escalating or de-escalating target doses based on the dose to organs at risk. Yet, ART workflows add complexity into the radiation therapy planning and delivery process that may introduce additional uncertainties. This work sought to review presently available ART workflows and technological considerations such as image quality, deformable image registration, and dose accumulation. Quality assurance considerations for ART components and minimum recommendations are described. Personnel and workflow efficiency recommendations are provided, as is a summary of currently available clinical evidence supporting the implementation of ART. Finally, to guide future clinical trial protocols, an example ART physician directive and a physics template following standard NRG Oncology protocol is provided.
UR - http://www.scopus.com/inward/record.url?scp=85100531472&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85100531472&partnerID=8YFLogxK
U2 - 10.1016/j.ijrobp.2020.10.021
DO - 10.1016/j.ijrobp.2020.10.021
M3 - Review article
C2 - 33470210
AN - SCOPUS:85100531472
SN - 0360-3016
VL - 109
SP - 1054
EP - 1075
JO - International Journal of Radiation Oncology Biology Physics
JF - International Journal of Radiation Oncology Biology Physics
IS - 4
ER -